AR078552A1 - Derivados de feniloxadiazol como agentes inhibidores de las pgds - Google Patents
Derivados de feniloxadiazol como agentes inhibidores de las pgdsInfo
- Publication number
- AR078552A1 AR078552A1 ARP100103650A ARP100103650A AR078552A1 AR 078552 A1 AR078552 A1 AR 078552A1 AR P100103650 A ARP100103650 A AR P100103650A AR P100103650 A ARP100103650 A AR P100103650A AR 078552 A1 AR078552 A1 AR 078552A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- acid addition
- addition salts
- phenyloxadiazol
- Prior art date
Links
- HTDLSAGEOYDVSJ-UHFFFAOYSA-N 4-phenyloxadiazole Chemical class O1N=NC(C=2C=CC=CC=2)=C1 HTDLSAGEOYDVSJ-UHFFFAOYSA-N 0.000 title 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title 1
- 101710145576 Prostaglandin-H2 D-isomerase Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 10
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se refiere a una composicion farmacéutica que comprende el compuesto, compuestos intermedios y a un procedimiento para fabricar dichos compuestos, y al uso del compuesto para tratar trastornos inflamatorios y/o alérgicos, particularmente trastornos tales como rinitis alérgica, asma, enfermedad pulmonar obstructiva cronica (COPD) y degeneracion macular relacionada con la edad (AMD) Reivindicacion 1: Un compuesto de formula (1) en la que R1 es hidrogeno o alquilo C1-6, R2 es hidrogeno, halogeno o alquilo de C1-3, y R3 es hidroxialquilo; o una de sus sales farmacéuticamente aceptables. Reivindicacion 17: Un compuesto de formula 2 o una de sus sales de adicion de ácidos. Reivindicacion 18: Un compuesto de formula 3 o una de sus sales de adicion de ácidos. Reivindicacion 19: Un compuesto de formula 4. Reivindicacion 20: Un compuesto de formula 5. Reivindicacion 22: El compuesto segun la reivindicacion 21 que es de formula 6 o una de sus sales de adicion de ácidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24969309P | 2009-10-08 | 2009-10-08 | |
| FR1056094 | 2010-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078552A1 true AR078552A1 (es) | 2011-11-16 |
Family
ID=43606440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103650A AR078552A1 (es) | 2009-10-08 | 2010-10-07 | Derivados de feniloxadiazol como agentes inhibidores de las pgds |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9469627B2 (es) |
| EP (1) | EP2486024B1 (es) |
| JP (2) | JP5753176B2 (es) |
| KR (1) | KR101701135B1 (es) |
| CN (3) | CN107875155A (es) |
| AR (1) | AR078552A1 (es) |
| AU (1) | AU2010303439B2 (es) |
| BR (1) | BR112012007635B1 (es) |
| CA (1) | CA2776242C (es) |
| DK (1) | DK2486024T3 (es) |
| ES (1) | ES2543011T3 (es) |
| IL (1) | IL218967A (es) |
| MA (1) | MA33725B1 (es) |
| MX (1) | MX2012003021A (es) |
| NZ (1) | NZ599099A (es) |
| PH (1) | PH12012500676A1 (es) |
| RU (2) | RU2015151129A (es) |
| SG (1) | SG179199A1 (es) |
| TW (1) | TWI508960B (es) |
| UY (1) | UY32938A (es) |
| WO (1) | WO2011044307A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| CN108430992A (zh) | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| EP3630738B1 (en) * | 2017-05-22 | 2023-07-19 | Egis Gyógyszergyár Zrt. | Process for the production of ozanimod |
| EP3638672A1 (en) | 2017-06-13 | 2020-04-22 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds as h-pgds inhibitors |
| EP3724197A1 (en) | 2017-12-13 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Fused pyridines which act as inhibitors of h-pgds |
| JP2022506850A (ja) | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
| US20230339937A1 (en) | 2020-06-19 | 2023-10-26 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| EP4450502A4 (en) | 2021-12-17 | 2025-06-11 | Sato Pharmaceutical Co., Ltd. | AZAINDOLE DERIVATIVE INHIBITING H-PGDS |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5176132A (en) | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
| DE10117823A1 (de) | 2001-04-10 | 2002-10-17 | Merck Patent Gmbh | Oxalsäurederivate |
| MXPA04009095A (es) * | 2002-03-19 | 2004-12-06 | Ono Pharmaceutical Co | Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo. |
| IL166782A0 (en) | 2002-08-16 | 2006-01-15 | Aventis Pharma Inc | Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| KR20060135901A (ko) * | 2004-04-21 | 2006-12-29 | 쉐링 코포레이션 | 피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]피리미딘아데노신 Ａ2ａ 수용체 길항제 |
| JP5209181B2 (ja) * | 2005-03-15 | 2013-06-12 | 富士フイルム株式会社 | 化合物、組成物、位相差板、楕円偏光板および液晶表示装置 |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) * | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| CN100556905C (zh) * | 2005-09-08 | 2009-11-04 | 国家南方农药创制中心江苏基地 | 吡唑酰胺类化合物及其中间体和以该类化合物为活性成分的有害生物防治剂 |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| PE20110118A1 (es) | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| CA2679198C (en) * | 2007-02-26 | 2011-07-12 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| DK2142516T3 (da) | 2007-03-30 | 2013-04-15 | Sanofi Sa | Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| WO2010080653A1 (en) | 2009-01-12 | 2010-07-15 | The Government Of U.S.A, As Represented By The Secretary Of The Navy | Composite electrode structure |
| BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
-
2010
- 2010-10-07 BR BR112012007635-3A patent/BR112012007635B1/pt not_active IP Right Cessation
- 2010-10-07 PH PH1/2012/500676A patent/PH12012500676A1/en unknown
- 2010-10-07 CA CA2776242A patent/CA2776242C/en active Active
- 2010-10-07 CN CN201711114032.4A patent/CN107875155A/zh active Pending
- 2010-10-07 CN CN201710240652.6A patent/CN106943407A/zh active Pending
- 2010-10-07 AU AU2010303439A patent/AU2010303439B2/en not_active Ceased
- 2010-10-07 ES ES10765724.9T patent/ES2543011T3/es active Active
- 2010-10-07 KR KR1020127008972A patent/KR101701135B1/ko active Active
- 2010-10-07 TW TW099134129A patent/TWI508960B/zh active
- 2010-10-07 RU RU2015151129A patent/RU2015151129A/ru not_active Application Discontinuation
- 2010-10-07 SG SG2012018933A patent/SG179199A1/en unknown
- 2010-10-07 RU RU2012118756/04A patent/RU2572608C2/ru active
- 2010-10-07 CN CN201080055808XA patent/CN102666508A/zh active Pending
- 2010-10-07 JP JP2012533302A patent/JP5753176B2/ja active Active
- 2010-10-07 WO PCT/US2010/051727 patent/WO2011044307A1/en not_active Ceased
- 2010-10-07 EP EP20100765724 patent/EP2486024B1/en active Active
- 2010-10-07 AR ARP100103650A patent/AR078552A1/es unknown
- 2010-10-07 DK DK10765724.9T patent/DK2486024T3/en active
- 2010-10-07 NZ NZ599099A patent/NZ599099A/xx not_active IP Right Cessation
- 2010-10-07 MX MX2012003021A patent/MX2012003021A/es not_active Application Discontinuation
- 2010-10-08 UY UY0001032938A patent/UY32938A/es not_active Application Discontinuation
-
2012
- 2012-04-01 IL IL218967A patent/IL218967A/en active IP Right Grant
- 2012-04-04 US US13/439,511 patent/US9469627B2/en active Active
- 2012-05-04 MA MA34835A patent/MA33725B1/fr unknown
-
2015
- 2015-05-20 JP JP2015102335A patent/JP5897186B2/ja active Active
-
2016
- 2016-09-07 US US15/258,892 patent/US9937175B2/en active Active
-
2018
- 2018-02-23 US US15/903,337 patent/US20190000845A1/en not_active Abandoned
- 2018-09-20 US US16/137,241 patent/US20190262338A1/en not_active Abandoned
-
2022
- 2022-11-22 US US17/992,553 patent/US20230190747A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2006000210A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| ECSP14013173A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida | |
| UY32938A (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
| MY154895A (en) | Pyrimidine hydrazide compounds as pgds inhibitors | |
| BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| CO6680645A2 (es) | Inhibidores de oxadiazol de la producción de leucotrieno | |
| CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
| SV2009002861A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| MA35285B1 (fr) | Indazoles | |
| PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| EA201792072A2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
| PE20070081A1 (es) | Derivados de 2,6-quinolinilo y preparaciones que los comprenden | |
| HN2010002403A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| ECSP088257A (es) | Derivados de amida | |
| CO6710902A2 (es) | Inhibidores de oxadiazol de la producción de leucotrienos | |
| AR080527A1 (es) | Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2 | |
| CU20090083A7 (es) | Análogos de pirazol | |
| EA201070917A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты | |
| UA116480C2 (uk) | Похідна біфенілу та спосіб її одержання |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |